NeurAxis (NASDAQ:NRXS) Issues Earnings Results, Misses Expectations By $0.09 EPS

NeurAxis (NASDAQ:NRXS) announced its quarterly earnings results on Monday. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09), RTT News reports. During the same quarter in the previous year, the company posted ($0.32) earnings per share.

NeurAxis Stock Up 13.5%

NeurAxis stock traded up $0.27 during midday trading on Monday, hitting $2.27. 4,969 shares of the stock were exchanged, compared to its average volume of 18,321. The company has a fifty day simple moving average of $2.07 and a two-hundred day simple moving average of $2.44. NeurAxis has a 52 week low of $1.33 and a 52 week high of $3.78. The stock has a market capitalization of $16.37 million, a PE ratio of -1.18 and a beta of 3.34.

Insider Buying and Selling at NeurAxis

In other news, major shareholder Brian Hannasch bought 18,065 shares of the company’s stock in a transaction dated Monday, April 21st. The shares were bought at an average cost of $1.73 per share, with a total value of $31,252.45. Following the acquisition, the insider now owns 775,966 shares in the company, valued at $1,342,421.18. This trade represents a 2.38% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 26.40% of the company’s stock.

NeurAxis Company Profile

NeurAxis, Inc, a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.